Affymetrix Inc.

Affymetrix Inc. of Santa Clara, Calif., has given nonexclusive access to Epigenomics AG of Berlin for its microarray technology. With this agreement, the German company will be able to develop and market microarray-based in vitro diagnostic tests for cancer and other diseases using Affymetrix’s DNA methylation methods.





LATEST NEWS

• The Winds of Change Are Blowing Through the Photonics Industry
  May 3, 2024
• PsiQuantum to Build Utility-Scale Quantum Computer in Australia
  May 3, 2024
• Tyndall, MIT Partner on Sustainable Chip Production Processes: Week in Brief: 5/3/24
  May 3, 2024
• Headwall Taps Jim Gareau to Lead Optical Components and Assemblies Unit
  May 2, 2024
• Cognex Names Former Siemens VP Dennis Fehr CFO
  May 2, 2024
• 3D Holography Integrated Glasses Could Unlock Mixed Reality
  May 2, 2024
• Generative AI Achieves Superresolution with Minimal Tuning
  May 2, 2024
• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024